ENTB Financials Monday, July 14, 2014 12:41:25 PM
Post# of 45
Entest BioMedical Inc.
Period Ending Aug 31, 2013 Aug 31, 2012 Aug 31, 2011 Aug 31, 2010
Total Revenue - - 349 -
Cost of Revenue 37 64 89 -
Gross Profit (37) (64) 260 -
Operating Expenses
Research and Development - 6 109 21
Sales, General and Admin. 626 742 1,062 517
Non-Recurring Items - - - -
Other - - - -
Operating Income (663) (812) (911) (538)
Income From Continuing Operations
Add'l Income/Expense Items (449) (664) - -
Earnings Before Interest and Tax (1,112) (1,476) (911) (538)
Interest Expense 182 410 41 7
Earnings Before Tax (1,294) (1,886) (952) (545)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (1,294) (1,904) (952) (545)
Non Recurring Events
Discontinued Operations (35) (4) - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (1,328) (1,908) (952) (545)
Preferred Stock and Other Adjustments - (32) - -
Net Income Applicable to Common Shareholders (1,328) (1,922) (952) (545)